title: Long-term therapy for uremic bleeding: effects of conjugate estrogens on the expression of platelet surface receptors for von Willebrand factor and fibrinogen (GPIb and GPIIb/IIIa glycoproteins)
authors.forename: F
authors.initials: F
authors.lastname: Salvati
authors.forename: M
authors.initials: M
authors.lastname: Liani
authors.forename: M
authors.initials: M
authors.lastname: Golato
mesh_terms: D015703:Antigens, CD / Q000096:biosynthesis / Q000187:drug effects; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D003080:Cold Temperature; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005340:Fibrinogen / Q000187:drug effects* / Q000378:metabolism; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D006801:Humans; D007275:Injections, Intravenous; D039661:Integrin beta3; D016023:Integrins / Q000096:biosynthesis / Q000187:drug effects; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000096:biosynthesis / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000096:biosynthesis / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000096:biosynthesis / Q000187:drug effects; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D014841:von Willebrand Factor / Q000187:drug effects* / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D004967:Estrogens; D039661:Integrin beta3; D016023:Integrins; D019038:Platelet Glycoprotein GPIb-IX Complex; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; C032193:glycoprotein receptor GPIb-IX; D014841:von Willebrand Factor; D004921:Erythropoietin; D005340:Fibrinogen